The Value of Rapid Antigen Tests to Identify Carriers of Viable SARS-CoV-2 - Shidlovskaya, Elena V.; Kuznetsova, Nadezhda A.; Divisenko, Elizaveta V.; Nikiforova, Maria A.; Siniavin, Andrei E.; Ogarkova, Daria A.; Shagaev, Aleksandr V.; Semashko, Maria A.; Tkachuk, Artem P.; Burgasova, Olga A.; Gushchin, Vladimir A. (medRxiv, 2021)
The search for effective methods to detect patients who excrete a viable virus is one of the urgent tasks of modern biomedicine. In the present study, we examined the diagnostic value of two antigen tests BIOCREDIT COVID-19 Ag (RapiGEN Inc., Korea) and SGTI-flex COVID-19 Ag (Sugentech Inc., Korea) for their diagnostic value in identifying patients who excrete viable SARS-CoV-2. As part of the study, we examined samples from 106 patients who had just been admitted to the hospital, who had undergone quantitative RT-PCR and assessment of viability of SARS-CoV-2 using cell culture. Sensitivity was 0.786 (0.492–0.953) for SGTI-flex COVID-19 Ag and 1 (0.768– 1) for Biocredit COVID-19 Ag. Specificity of rapid tests was significantly higher than that of RT-PCR and was 0.663 (0.557–0.758) and 0.674 (0.568–0.768) for SGTI-flex COVID-19 Ag and Biocredit COVID-19 Ag versus 0.304 (0.213–0.409) obtained for PCR. Thus, for tasks of identifying viable SARS-CoV-2 during screening of conditionally healthy people, as well as monitoring those quarantined, rapid tests show significantly better results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors: E.V.S., N.A.K., E.V.D., M.A.N., A.E.S., D.A.O., M.A.S., A.P.T., O.A.B., V.A.G. had been supported by the Ministry of Health of the Russian Federation, Government assignment number AAAA-A20-120113090054-6.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was approved by the Local ethic committee of the Moscow First Infectious Diseases Hospital (the Protocol #2 dated 2021-01-22).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article (and its supplementary information files).